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Abstract:  
Optical microscopy has a diffraction-limited 
resolution of ~250nm. Fluorescence methods (e.g. 
PALM, STORM, STED) beat this, but they are still 
limited to 10’s nm, and the images are an indirect 
pointillist representation of only part of the original 
object. Here we describe a way of combining a 
sample preparation technique taken from 
histopathology, with a probe-based nano-imaging 
technique, (s-SNOM) from the world of Solid State 
Physics. This allows us to image subcellular structures 
optically, and at a nanoscale resolution that is ~100x 
better than normal microscopes. By adding a 
tuneable laser source, we also demonstrate mid-
infrared chemical nano-imaging (MICHNI) in human 
myeloma cells and we use it to map the binding sites 
of the anti-cancer drug bortezomib to <10 zL (<10-20 
L) sized intracellular components. MICHNI is label free 
and can be used with any biological material and 
drugs with specific functional chemistry. We believe 
that its combination of speed, cheapness, simplicity, 
safety and chemical contrast promises a 
transformative impact across the life sciences.   
 
One Sentence Summary: Universal optical imaging of 
nanoscale biology and chemistry at a fraction of the 
effort and cost of electron microscopy. 
 
Introduction. 
In the past two decades a range of fluorescence cell 
microscopy techniques1 have been developed which 
can achieve down to ~10 nm spatial resolution2,3, i.e. 
substantially beating the usual limits ( ~250nm) set by 
optical diffraction. However,  achieving this 
performance relies on specialised labelling4 with 
bespoke “fluorescers” that have to be individually 
developed to  suit the problem at hand. This limits the 
techniques’  applicability as well as risking perturbing 
the biology5,6. The alternative route to sub-diffraction 
so-called “ultrastructural” information, electron 
microscopy, (EM), requires complex and time-
consuming sample preparation that risks 
compromising the sample’s integrity.  Samples have 
to be stained with heavy metals to give usable 
electron contrast, and they have to be rendered into 
a form that is electrically conductive and can 
withstand the vacuum environment within the EM, a 
process that typically takes weeks.  
 
In the world of  physics research there are several 
scanning probe-based imaging methods, mostly 
based on atomic-force-microscopy,  that have 
demonstrated morphological imaging resolutions7,8 
significantly below 20nm.  A number of Mid-infrared 
(mid-IR) scanning probe techniques that are optical 
extensions of AFM, are also available (see S1, 
 
Fig. 1. Schematic of the arrangement for Mid-Infrared Chemical Nano-
Imaging (MICHNI) of a human myeloma cell. The cell is first  formalin-
fixed, dried,  embedded in wax, sliced ( ~1µm thick), and transferred to 
a smooth glass slide. The wax is then removed leaving only the bio-
material behind on the glass, in a form that is now suitable for imaging 
and analysing with s-SNOM. The s-SNOM works by detecting the laser 
light (of wavelength λ=9.8 μm in this example) that is backscattered 
from the tiny region where the sharp probe of an atomic-force-
microscope (AFM) meets the sample (see S1, supplimentary material).  
The sharp conducting AFM probe tip concentrates the laser  into a 
nanoscale region of the sample, and gives an image resolution ~ 2,000 
times better than conventional diffraction limits. In this plot the height 
denotes the sample topography (as determined by the AFM). The 
colour scale denotes the infrared scattering magnitude, s2, from the s-
SNOM, itself is a measure of the optical absorption of the small patch 
of the bio-material underneath the probe at that point in the scan. 
MICHNI chemical analysis at a nanoscale  resolution can be achieved 
by combining images obtained by tuning the laser wavelength to 
various IR absorption features arising from known chemical moieties in 
the sample. The images of the probe and laser beam here are 
computer generated for illustration purposes only and are not to scale. 
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supplementary material). However, these only work 
with samples that are flat, dry and dimensionally 
stable down to the nm level, and they only probe 
down to a depth commensurate with the spatial 
resolution9, so they yield essentially surface 
information.  
 
These technologies have been available for more 
than 2 decades, and reliable, rapid and easy to use 
commercial instruments are now available. However, 
for the above reasons, thus far they have been 
applied only to artificial test samples, e.g. gold 
particles 10, or isolated proteins11 on silicon. 
 
 Here we show how 
one of these probe-
based techniques, 
scattering-type 
scanning near field 
optical microscopy 
(s-SNOM, Fig. 1), can 
be adapted to image 
general biological 
samples.  The label-
free imaging of 
cellular structures 
introduced in this 
study potentially 
offers a high 
throughput 
alternative to EM 
that is capable of 
aiding disease 
diagnosis by 
identifying changes 
in intracellular 
components.   
 
As a proof-of-principle demonstration of the ability of 
MICHNI to locate the site of a drug’s action, we here 
study the drug compound Bortezomib (BTZ). BTZ is an 
important clinically approved therapeutic against 
Multiple Myeloma12, (see S5, S6 supplementary 
materials). It is well suited to the MICHNI approach 
because its chemical makeup gives it a distinctive 
absorption signature in the mid-IR that sets it apart 
from the cellular bio-material. Its mechanism of 
action proceeds through inhibition of proteasomes – 
intracellular complexes that break down proteins.   As 
a proteasome inhibitor, one might a priori expect the 
BTZ signal to peak in regions of high proteasome 
concentration within the cell.  
  
For sample preparation , we use a variant of the 
standard histopathological “formalin-fixed, paraffin-
embedded” (FFPE) method (see S4, supplementary 
materials). We find that this approach can be 
employed to turn any biological sample into a 
collection of stably mounted nanoscale bio-material 
structures13 that can be  imaged with  s-SNOM14. In 
our case, the s-SNOM (Fig. 1) is equipped with an 
array of widely tuneable mid-infrared quantum 
cascade lasers (QCLs) that span the 5 µm < λ < 11 µm  
range15,16 so we can perform nanoscale spectroscopy 
by combining images taken over a wide range of 
wavelengths.  
 
These mid-IR wavelengths lie in the so-called 
“chemical fingerprint” spectral region, where a given 
light wavelength is absorbed in a localised and bond-
specific vibrational transition in the corresponding 
chemical moiety. These vibronic absorption features 
are well – characterised and have been used for many 
years, both for chemical analysis, and to generate 
chemical images using, e.g. Fourier transform 
infrared (FTIR) spectroscopy17.  MICHNI exploits this 
link between mid-IR spectral absorption and chemical 
composition to allow one to infer “mid-IR chemical 
nano-imaging” (MICHNI) information from 
combinations of mid-IR s-SNOM images.  
 
Results. 
Figure 2 shows the AFM topography, and the second 
harmonic near-field scattered amplitude, s2, of a 
section of a single RPMI-8226 myeloma cell. The cell 
has been  pre-treated with BTZ, before being 
 
Fig. 2. Images of a sub-micron thick section of a single dried human myeloma cell mounted on a glass slide. (A) Topography, 
as measured with an AFM and (B) near-field scattered amplitude, s2, measured with an s-SNOM at a wavelength of λ=9.8 
µm (1020 cm-1), where deep sub-cellular features, tentatively identified here as the cell nucleus and bilayer membrane, are 
visible. The black dashed and green squares in (B) indicate the regions that are studied in more detail in Figs. 3 and 4, 
respectively. 
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prepared for imaging (see S4, 
supplementary material) with the FFPE-
based sample preparation protocol13.  
 
The AFM image (Fig. 2(A)) is essentially a 
height map, showing the morphological 
profile of the biological material in the 
dried section as it is distributed across the 
smooth glass slide. It is generated 
mechanically, as the probe tip scans across 
the sample, like a nanoscale version of a 
record needle. Its lateral resolution is 
determined by the AFM tip diameter, and 
there is no chemical contrast. In 
comparison, the MICHNI image (Fig. 2(B)) is 
notably sharper and resolves a host of extra 
sub-cellular components.  
 
Zooming in (Fig. 3(A) and (B)) on the black 
dashed square of Fig. 2(B) gives a visual 
indication of the resolution and contrast 
enhancement of the MICHNI image (Fig. 
3(B)) over the AFM one (Fig. 3(A)). Selecting 
a fine biological feature from the MICHNI 
image, in this case a ~15 nm high step 
(possibly of nuclear membrane material) at 
the edge of the  cell nucleus (Fig. 3(D)) and 
performing a line scan analysis at the 
smallest possible step size (0.5nm), (Fig. 3(E)) shows 
how the way that the so-called “Lightning-rod” effect 
that concentrates the optical fields under the 
conducting tip, has resulted in a ~5x resolution 
improvement of the s-SNOM over AFM.  
 
The observed ~2.3 nm MICHNI resolution 
corresponds to ~𝝀/𝟒, 𝟑𝟎𝟎 at the 𝝀 = 𝟗. 𝟖 μm 
imaging wavelength; this beats diffraction by >3 
decades.  In the s-SNOM literature9 with artificial test 
samples, sub ~20nm resolution figures have been 
reported previously. In our experiments, we found 
that this figure was often bettered (see 
supplementary material S10), but only in samples 
where there was strong chemical contrast, 
accompanied by only small height changes  that were 
comparable to or less than the ~10 nm tip radius. The 
latter is estimated here from the resolutions seen in 
the AFM images.  
 
If the step is higher than this, the tip has to ride up 
over it and, just as in AFM, this occurs over a lateral 
distance that is determined mechanically, by the tip 
radius. As the tip rides up the step, the effective tip-
sample separation changes, and this purely 
mechanical effect alters the nano-optics that 
determine the backscattering cross-section.   
 
The result is that the larger step heights will degrade 
the lateral resolution in the s-SNOM  image to similar 
values to the AFM one. This mechanism may have 
been limiting the observed s-SNOM resolution seen 
in previous experiments with artificial samples 
because they are typically fabricated by lithography 
techniques, where chemical contrast is always 
accompanied by a height step.  
 
The natural nanostructures studied here seem to be 
better for showcasing s-SNOM’s true resolution 
limits. 
 
The frequency-dependent phase of the backscattered 
light, 𝝋2(ν), is the key to the local chemical 
information that these images contain (see S2, 
supplementary material). In order to isolate the BTZ 
contribution to the optical response, we first take a 
zero-phase reference reading corresponding to a part 
of the image known to be glass (i.e. the lightest toned 
smooth parts of the s2-based images). This datum is 
used to generate a false-colour 𝝋2(ν) image (Fig. 3(C)), 
where the regions of increased optical absorption 
 
Fig. 3. Close-up of sub-cellular structures in the cytoplasmic region of the cell indicated by 
the 3 μm x 3 μm black dashed square in Fig. 2(B).   Shown are the (A) AFM topography, (B) 
near-field second-harmonic scattered magnitude, s2, and (C) scattered phase, 𝜑2. 
Observed structures in (B) are provisionally assigned to mitochondria (white arrows) and 
vesicles (blue arrows). (D) Magnified view of the edge of a cell nucleus on the glass 
substrate, where the blue arrow indicates the direction and extent of (E) a line-scan 
(averaged over a width equal to width of the arrow’s base) of the near-field scattered 
amplitude, s2, (red) and AFM height (black) across the boundary between the glass 
substrate and the nuclear material. Errors (estimated by the variance across the 5-pixel 
wide line scan region) are smaller than the plotting symbols.  
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due to BTZ cause 𝝋2(ν) to increase and show up as red 
“hot spots” in the image rendering. 
 
For quantitative spectroscopic analysis, we zoom in to 
an area (Fig. 4(A-C)) that corresponds to the 1.4 μm x 
1.4 μm green square in Fig. 2(B). The near-field phase, 
𝝋2(ν) image, shows strong BTZ hotspots (blue arrows) 
when the laser is tuned to the absorption peak of the 
BTZ (see S5, supplementary material). Sitting on one 
of these, and tuning the laser, generates an 
absorption peak at the same wavelength as is seen in 
a reference absorption spectrum (Fig. 4(D), inset) of a 
sample of pure BTZ taken separately in an FTIR 
spectrometer.  
 
This absorption peak is due to a boron-based group in 
the synthetic BTZ molecule (see S5, supplementary 
material) that has no analogue in natural biological 
material. This was checked with control experiments 
using undosed cells (see S8, supplementary material) 
that generated the spectra in Fig. 4 (D) denoted by 
the green squares.  
 
Although the BTZ absorption peak positions match 
very accurately, their widths differ because the FTIR 
reference spectrum is a measure of absorbed power 
in an unknown depth of pure drug, whereas the 
MICHNI signal approximates to a measure of 
absorption coefficient14 in a more dilute BTZ-
containing sample.  
 
In this instance the scattering from the glass substrate 
is much stronger than from the biological material, so 
the overall scattering amplitude, s2, tends to decrease 
with increasing thickness of the biological material18.  
 
The chemical contrast evident in, Fig. 4(D) is visible in 
features with volumes down to ~10 zL (10-23 m3). 
 
Discussion. 
 
The correspondence between the spectral signatures 
of the localised structures in the MICHNI images and 
the reference BTZ spectra argues strongly that we can 
map out the intracellular drug binding sites at, in this 
case, spatial resolutions down to ~2.3 nm.   
 
At the same time, the images contain a wealth of 
nanoscale structural information arising from non-
resonant mid-IR absorption in the biological material 
itself.  
 
At this early stage, we are not able to  identify the 
various intracellular elements with confidence. The 
various organelles are likely to shrink by unknown 
factors during the drying stage, and some structures 
may be more likely to adhere to the glass slide than 
others during the sample processing.  
 
Tentatively however, we identify oval mitochondria-
like structures (white arrows, Fig. 3 (B)) which, at 
~250 nm long, are roughly 50% smaller than those 
seen in EM images of these cell lines19. Also present 
are a range of spherical vesicle-like structures with 
diameters in the 140 nm – 450 nm range (blue 
arrows, Fig. 3(B)).   
 
Further MICHNI images of a range of different cells, 
which show similar reproducible cytoplasmic 
intracellular features, but are taken using different 
samples with and without BTZ, are presented in S7, 
supplementary material. Going forward, we believe 
that specialised tissue processing protocols20 will 
allow the morphology and scale of these structures to 
be better preserved during sample preparation, and 
for organelle shrinkage rates to be calibrated.  
 
Correlation experiments between MICHNI and EM 
would then enable these sub-cellular features to be 
visually identified as confidently as is done with EM at 
present. Similarly, correlation between MICHNI and 
Raman spectroscopy – a more established technique 
used to fingerprint spectra and map distributions of 
 
 
Fig. 4. MICHNI mapping of the anti-cancer drug Bortezomib (BTZ) in a 
human myeloma cell which is dosed with 8 µM BTZ. (A) The AFM 
topography of the magnified region indicated by the 1.4 μm x 1.4 μm 
green square in Fig. 2(B), The white dashed rectangle and the  blue 
square denote the averaging areas used for  acquiring the near-field 
signals for the glass reference and the vesicle-like object  respectively. 
The patch of vesicle-like material measured is ~9 nm thick with radius 
~60 nm. The near-field phase images, 𝜑2, at (B) 1020 cm-1 and (C) 
1000 cm-1 show vesicle-like structures with strong BTZ hotspots (blue 
arrows) and have been locally referenced to the zero-phase signal 
from the glass substrate. (D) Comparison of the local absorption from 
the BTZ dosed sample (blue circles) and undosed control sample (green 
squares; see S8, supplementary material), and the far-field absorption 
spectrum (black line) taken from a separate FTIR (see S3, 
supplementary material) spectral measurement of bulk BTZ (inset). 
Error bars correspond to the standard error of the mean values within 
the respective averaging regions. Where not shown, the error bars are 
smaller than the marker size. 
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specific molecules such as lipids inside cells21, but at 
much lower length scales than possible with MICHNI 
– could also be utilized to benchmark this technique. 
 
In conclusion, we have demonstrated MICHNI 
imaging of single cells and intracellular components  
with a spatial resolution that already rivals EM. We 
speculate that future MICHNI imaging studies will 
prove valuable in correlating proteasome localisation 
and inhibition in different cell types and under 
different conditions, thereby informing on the 
sensitivity of proteasome inhibition in certain disease 
states (i.e. multiple myeloma).  
 
A key point to note is that the FFPE sample 
preparation method used in MICHNI is already 
standard in pathology laboratories worldwide. The 
protocols for harvesting and preparing the tissue 
samples are already clinically approved and budgeted 
for, and reliable automated s-SNOM imagers are 
already commercially available. This suggests that the 
MICHNI technology could be readily incorporated 
into clinical pathology workflows in a way that could 
significantly improve the security and accuracy of a 
wide range of disease diagnoses, notably cancer.   
 
At its core, the opto-mechanical components in the 
imaging system are no more complex than a DVD 
player, and we believe that future mass produced 
MICHNI equipment could be engineered to be usable 
and affordable in a clinical setting in a way that is not 
possible with EM.  From the clinicians’ point of view, 
the impact would be akin to suddenly improving their 
microscope resolution performance by a factor of 
100. This would give them routine access to 
intracellular “ultrastructure” imaging information in a 
way that could revolutionise histopathology. 
 
In the scientific realm, MICHNI on its own has the 
potential for widespread applications across the 
fields of cancer, cellular pathology in general, and 
drug discovery. It could also offer useful correlative 
morphological and chemical information for research 
problems that are currently being studied by EM. 
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Materials and Methods. 
The MICHNI images presented in this study were 
generated using ~100 mW level tuneable (~900-1900 
cm-1) mid-infrared laser light generated by a 
switchable bank of commercial quantum cascade 
lasers (MIRcat, Daylight Solutions). The laser beam 
was focussed to the tip of a Pt/Ir-coated Silicon AFM 
probe (Arrow-NCPt, Nanoworld) in a commercial s-
SNOM (NeaSNOM, Neaspec). The AFM component of 
the system was set to give a mean probe height of ~50 
nm above the sample, and it was oscillating vertically 
with an amplitude of ~50 nm at its mechanical 
resonance frequency 𝜔 ≈ 280 kHz.  
 
The sample preparation process (see S4, 
supplementary material) is based on the formalin-
fixed-paraffin-embedded (FFPE) “gold standard” 
protocol13 that is used to make many tens of 
thousands of biopsy sections annually in hospital 
pathology laboratories for routine haematoxylin and 
eosin (“H&E”) based disease diagnoses. The process 
is semi-automated and takes ~ hrs (compared to 
~weeks for EM sample preparation).  
 
In most potential clinical applications, the samples 
would be harvested and processed this way in any 
event, so there is an argument that preparing clinical 
samples for MICHNI analysis is already clinically 
approved, and is effectively free and instantaneous. 
 
The principle modifications were to use a thinner 
section (estimated to be ~1 µm thick before 
dewaxing), so that the sample height fluctuations 
were kept within the allowable range of the AFM, and 
the omission of the final H&E staining and protection 
stages of the sample preparation protocol altogether. 
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Supplementary material: 
 
 
S1. Technical Description and Context of 
Spectroscopic Mid-Infrared Chemical Nano-Imaging 
(MICHNI) 
 
Our MICHNI approach is based on so-called 
“scattering-type” scanning near-field optical 
microscopyi (s-SNOM). An atomic force microscope 
(AFM) is used to position a sharp conducting probe to 
within a few nm of the object to be imaged, and a 
laser is focussed on the region where the two meet 
(Fig. 1). The sharp probe tip concentrates the optical 
field, by a nanoscale analogue of the “lightning rod” 
effect, to a region commensurate with its radius.  
 
An analysis of the backscattered light allows the 
optical response of the material just under the tipi to 
be measured. This gives an optical image whose 
spatial resolution is determined by the tip radius, and 
not the light wavelengthii. A spatial resolution of 
better than ~20 nm is routinely available with robust, 
commercially available probes. The optical image is 
built up by rastering the tip across the sample, and a 
standard AFM topography image is generated at the 
same time. 
 
Previous s-SNOM studies have been restricted to 
narrow wavelength range studies of solid state 
systems. Studies include PMMA test samplesiii,iv, 
metamaterial superlensesv,vi and oxidevii  and 
grapheneviii layers. In the biological realm, 
demonstrator trials have imaged cylindrical tobacco 
mosaic viruses deposited on Siix, and dried proteins in 
lipid bilayer fragments extracted from bacteria and 
mounted on goldx.  A related technique, based on 
AFM-photothermal effects, can yield diffraction-
beating micron-scale IR imagesxi,xii, but the resolution 
does not challenge optical microscopy and is 
insufficient to map out sub-cellular structure. 
 
The MICHNI images presented in this study were 
generated using  a NeaSNOM near field s-SNOM 
microscope, coupled with ~100 mW level tuneable 
(~900-1900 cm-1) mid-infrared laser light generated 
by a switchable bank of commercial quantum cascade 
lasers (MIRcat, Daylight Solutions). The s-SNOM was 
used with a Pt/Ir-coated Silicon AFM probe (Arrow-
NCPt, Nanoworld) whose tip radius is estimated as 
~10nm, although the image resolution observed in 
this work is finer than this due to the way it 
concentrates the field beneath its apexi.  
 
The IR light backscattered from the tip was detected 
by a low-noise LN2 cooled HgCdTe detector. The 
amount of scattered near-field optical signal depends 
on the tip-sample separation in a highly non-linear 
fashion, and this generates components at harmonics 
(nω) of the tip vibration frequency, ω, in the power 
spectrum of the backscattered light intensity.  
 
Analysis of the “approach curves” ii implies that the 
higher the harmonics generally contain a larger 
proportion of the optical near-field information, and 
should therefore give the best spatial resolution, with 
the lowest background component. However, there 
is a signal-to-noise trade-off because the harmonic 
optical power decreases with n. Signals demodulated 
at the n = 2 harmonic were used in this study. To 
further decouple near-field from far-field, a 
pseudoheterodyne interferometric detection scheme 
was employedxiii. 
 
S2 Extracting semi-Quantitative Spectroscopic Data 
from MICHNI. 
 
A full numerical analysis of the interaction between 
the laser radiation and the oscillating AFM tip is 
beyond the scope of this paper. However, the fact 
that, in solid samples, damping broadens the IR 
absorption peaks means that optical dispersion in the 
material is typically weak. This allows for an analytical 
model of the tip-sample interaction, (where the 
spherical tip is modelled as a point dipole) which, in 
turn, predicts that, the optical phase of the 
backscattered signal is proportional to the absorption 
coefficient of the material beneath the tip ii,iv,ix,x,xiv.  
  
Even if this “weakly dispersive” approximation is not 
reliable, given that the technique works with optical 
processes that are linear and therefore obey the 
principle of superposition, reliable concentration 
estimates can be obtained by measuring reference 
scattering phase values with the bare substrate, and 
subsequently recording the degree of phase shift as 
the tip is rastered over the bio-material ix,x. 
 
Small-molecule drugs are exogenous species and, in 
many cases, they contain chemical structures and 
functionality that give them a particularly distinctive 
mid-IR “fingerprint” spectrum. This can make them 
stand out from the normal absorption signature of 
biological material and makes them particularly 
suitable for mid-IR mapping (see S3).  
 
To analyse the MICHNI images, the spectroscopic 
signature of the BTZ was isolated by first acquiring a 
frequency dependent reference phase 
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value, 𝜑𝑔𝑙𝑎𝑠𝑠(𝜈), with the probe imaging a part of the 
glass substrate close to the sub-cellular structure of 
interest. This allowed the degree of phase shift 
corresponding to the BTZ absorption to be computed 
as (𝜑(𝜈) = 𝜑𝐵𝑇𝑍(𝜈) − 𝜑𝑔𝑙𝑎𝑠𝑠(𝜈)). The backscattered 
amplitude was then normalised to that of the glass, 
(𝑠(𝜈) = 𝑠𝐵𝑇𝑍(𝜈)/𝑠𝑔𝑙𝑎𝑠𝑠(𝜈)). This allowed the 
imaginary component of the backscattered signal, 
𝐼𝑚(𝜎) to be computed as 𝐼𝑚(𝜎) = 𝑠 sin(𝜑).  
 
𝐼𝑚(𝜎) is itself proportional to the local absorption 
coefficient of the material beneath the tipi. For the 
BTZ experiments, this measure of the local absorption 
showed the pronounced spectral resonance at 1020 
cm-1 shown in Fig. 4(g)). 
 
At the time of writing, this quantitative analysis 
cannot be performed in, for example, the depths of 
the cell nucleus because of difficulties in getting 
reliable phase calibrations due to the large height 
variations across the nucleus. 
 
The quantitative spectroscopic analysis shown in Fig. 
4(D) was achieved by averaging local absorption (see 
above) of the vesicle-like object (125 nm x 125 nm 
blue square in Fig. 4(A)) and normalising with respect 
to that of the substrate (250 nm x 500 nm white 
dashed rectangle). In this manner, sweeping the 
illumination wavelength provides a spectrum of the 
feature’s local absorption, which can be directly 
compared with the known far-field absorption 
spectra of various chemicals (e.g. BTZ). By this means, 
we confirm the presence of BTZ in the vesicle-like 
structure imaged.  The local absorption signal is 
averaged over a ~10 nm thick patch of material, 
which corresponds to a material volume of ~10-23 m3, 
(~10 zL).  
 
The local absorption spectrum in Fig. 4(D) of the BTZ 
dosed sample (blue circles) shows good qualitative 
agreement with the far-field absorption spectrum 
(black line), which was obtained with a reference 
sample of pure BTZ measured in a conventional FTIR 
spectrometer (see S3). Both spectra show a sharp 
peak at 1020 cm-1, with a difference in linewidth that 
is likely due to over-absorption in the reference 
sample whose optical thickness was not known due 
to the geometry of the “attenuated total reflection” 
method used (see S3). 
 
S3 Obtaining reference Bortezomib Spectra using 
Far-field infrared absorption spectroscopy 
 
A pure sample of BTZ was acquired from Selleckchem 
at 99.94% purity (catalogue number S1013, batch 
number S101315). A commercial FTIR spectrometer 
(Frontier FT-IR/MIR, PerkinElmer) equipped with a 
KBr window, an ATR (attenuated total reflectance) 
accessory and a LiTaO3 detector was used to record 
the IR spectrum in the 4000-650 cm-1 range, at 4 cm-1 
resolution and with a scan speed of 0.2 cm sec-1.  
 
Approximately, 2 mg of solid BTZ was applied over the 
exposed KBr ATR crystal surface using a carefully 
cleaned sample mounting plate. The knob of the 
pressure arm was then swung over the sample and 
knob was rotated to apply pressure. Finally, the ATR 
spectrum of BTZ was recorded (Fig. S1) and 
normalised against a background air spectrum. 
 
S4 Details of Cell preparation and Drug Treatment. 
 
All the studies were performed using RPMI-8226 
myeloma cells, cultured in RPMI-1640 medium. The 
medium was supplemented with 10% FCS, penicillin 
(100 U/ml), 5% glutamine, and streptomycin sulphate 
(100 μg/ml). Cells were cultured at 37 °C in a 
humidified atmosphere containing 5% CO2. Cells were 
harvested, washed twice with PBS, and counted prior 
to BTZ treatment. 1x107 cells were incubated with 
8µM of BTZ in vehicle (0.1% DMSO) for 1 h at 37 °C. 
For the undosed control samples, the BTZ incubation 
step was omitted. Cells were washed twice in PBS 
before being pelleted for paraffin embedding and 
sectioning. 
 
Pellets of washed RPMI-8226 myeloma cells were 
fixed in 4% paraformaldehyde for 30 min at room 
temperature. These were processed for embedding 
in paraffin as per published protocolxv. Cell blocks 
were cut into ~1 µm sections using a microtome 
before being mounted onto “charged” glass slides 
(Thermo Scientific product code J2800AMNZ) that 
had been specially treated to promote tissue 
adhesion. To further enhance adhesion, the glass 
slides were heated to 60 °C for 10 min before 5 min 
of cooling at room temperature. The mounted 
samples were dewaxed by being immersed in a series 
of two xylene, followed by three ethanol baths, each 
for 5 min. 
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The MICHNI images are all taken at ambient pressure 
and temperature, and the cells are unstained and 
unlabelled throughout.  
 
At present the specimens are imaged while they are 
dry, so whilst the chemical information is well 
preserved, the details of the sub-cellular structural 
morphology will be influenced by shrinkage rates that 
may vary between the different sub-cellular 
components. This makes it difficult to be confident 
when comparing MICHNI images with those in the 
EM-based literature.  
 
Looking ahead, we expect that a combination of 
operator experience, coupled with correlation 
studies and developments on fixing protocols will 
surmount this obstacle. 
 
S5 Comparison of Bortezomib and Human tissue 
mid-infrared spectra 
 
Bortezomib (BTZ) is a promising candidate for 
spectroscopic mapping, as it has an unusual chemical 
structure, containing boron, and an associated B-C 
bond (Fig. S1(A)), which is rarely found in nature. This 
B-C bond yields a strong, sharp absorption resonance 
xvi in a spectral region where the absorption spectrum 
of biological material is normally featurelessxvii (Fig. 
S1(B)). 
 
 
S6 Correlation between MICHNI images and the 
Pharmacology of Bortezomib 
 
BTZ is a clinically approved agent for the treatment of 
multiple myelomaxviii, and its mechanism of action 
proceeds through inhibition of proteasomes – cellular 
complexes that break down proteins.  
 
As a proteasome inhibitor, one might a priori expect 
the BTZ signal to peak in regions of high proteasome 
concentration in the cell. 
 
 Based largely on cell-fractionation studiesxix, regions 
of proteasome activity and distribution are thought 
to typically include the outer endoplasmic reticulum, 
cytoskeleton and centrosomes, nuclei (but not 
nucleoli) and cytoplasm.  
 
We speculate that future MICHNI imaging studies will 
prove valuable in correlating proteasome localisation 
and inhibition in different cell types and under 
different conditions, thereby informing on the 
sensitivity of proteasome inhibition in certain disease 
states (i.e. multiple myeloma). 
 
S7 Additional MICHNI images of single cells and sub-
cellular structures 
 
 
Fig. S1. (A) The unusual chemical structure of Bortezomib (BTZ) 
results in (B) an infrared far-field absorption spectrum (blue) that is 
highly distinctive compared with typical human tissue (red; 
reproduced with permission from (36)). 
 
 
Fig. S2. MICHNI imaging of a single undosed human myeloma cell as 
a control. (A) AFM topography and (B) near-field amplitude, s2, at 
1020 cm-1 of a single cell. The purple square indicates the scanning 
region of Fig. 4(D) that is used as a control for spectroscopic mapping 
of BTZ. The red dashed square is shown magnified in (D) along with 
the corresponding topography in (C). As in the main text, the white 
and blue arrows in (C) indicate mitochondria-like and vesicle-like sub-
cellular structures, respectively. 
 
 
Fig. S3. MICHNI imaging of a single human myeloma cell dosed with 8 µM 
BTZ. (A) AFM topography and (B) near-field amplitude, s2, at 1020 cm-1 of 
a single cell with a large slice of the nucleus. 
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In order to further evidence the ability of the MICHNI 
technique to reproducibly image the sub-cellular 
structure of single cells, this section provides 
additional images. They were taken at different times 
over a period of several months, in different cells, in 
different samples, with and without BTZ dosing.  The 
point where the microtome has sliced the nucleus 
also differs significantly. In Fig. S2 only a small sliver 
of nuclear material has been sliced off, leaving only a 
few areas ≳0.6 µm high, whereas in Fig. S3 and Fig. 2 
in the main text, the knife has sliced through the body 
of the nucleus leaving a thicker (~1 µm) residual 
nuclear section. However, all the images show similar 
cytoplasmic sub-cellular structures.  
 
In particular, zooming in (Fig. S2(D)) reveals 
mitochondria-like and vesicle-like features identical 
to those of Fig. 3 in the main text, arguing that both 
are genuinely biological in origin. 
 
S8 Control MICHNI measurements in undosed tissue 
 
To ensure that this spectral peak in Fig. 4(D) is not 
simply a signature of the endogenous chemistry of 
the sub-cellular structures, the spectroscopic near-
field measurements were repeated with a control 
sample that had not been dosed with BTZ. An 
overview of the particular cell used in the control 
measurements is given in Fig. S2, which also indicates 
the scanning region of the control measurements 
that are depicted in Fig. S4(A-C). Repeating the 
spectroscopic analysis for this control yields the 
spectrum shown by the green squares in Fig. 4(D). The 
control does not exhibit the characteristic resonant 
absorption peak of BTZ, and we were unable to find 
any part of the control cell image that did. This is by 
way of confirmation that our MICHNI technique has 
been able to specifically map BTZ in a single nanoscale 
vesicle-like structure. 
 
 
S9 The relative contributions of the 
near-field amplitude and phase to 
spectral changes in Im(σ) 
 
Strictly speaking, it is the imaginary 
component of the near-field 
scattering amplitude that is 
proportional to local absorptioni, 
however it is often the case that the 
majority of the chemical contrast 
signal in the imaginary component 
spectrum comes from the 
contribution of the near-field phase variation.  
 
This is clearly shown in Fig. S5, whereby the 
amplitude spectrum is relatively flat compared with 
the phase spectrum. Comparing these figures with 
Fig. 4(D) of the main text, it is clear that the phase and 
imaginary spectra are in good agreement. 
 
S10 Additional measurements evidencing sub-5 nm 
spatial resolution in MICHNI images 
 
Figure S6 shows a typical linescan across the 
boundary between a vesicle and glass, with a ~4nm 
spatial resolution. In this example both the height 
change (~60nm), and step size (2nm) are larger than 
the 15nm height change/0.5nm step size in figure 
3(D) in the main text.  
 
In many cases the s-SNOM images we observed were 
considerably sharper than the AFM ones. It appears 
 
Fig. S4. MICHNI spectroscopic imaging of sub-cellular structures in undosed control tissue. (A) 
Topography of the region indicated by the 1.4 μm x 1.4 μm red dashed square in Fig. S2(B). The green 
square and the white dashed rectangle show the averaging areas for acquisition of vesicle-like and 
glass near-field signals, respectively. The near-field phase images, 𝜑2, at (B) 1020 cm-1 and (C) 1000 
cm-1 have been referenced to the zero-phase signal from the glass substrate. 
 
 
 
 
Fig. S5. (A) Near-field amplitude and (B) phase spectra of BTZ in a 
cell (as shown in Fig. 4.) 
 
 
Fig. S6. (A) Near-field amplitude showing sharpness of detail in a  
sub-cellular structure. (B) Line profile across the glass-vesicle 
boundary indicated by the red arrow in (A) shows ~4 nm resolution 
probably limited by the step size in this instance. 
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that the sample area that generates the s-SNOM 
signal under these experimental settings, is rather 
smaller than the tip radius, due to the “lightning rod 
effect” that concentrates the light fields.  
 
The best s-SNOM resolution figures were observed 
with features with strong chemical contrast (e.g. glass 
vs. biological tissue) and the smallest possible height 
changes. The especially fine detail seen in these 
MICHNI images argues that, as yet, nature is better at 
making these than man. 
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